Foldamer M4 Mitigates Alzheimer’s Pathology by Stabilizing Aβ Helical Domains
Researchers have identified a synthetic peptidomimetic foldamer, designated M4, as a potent therapeutic candidate for Alzheimer’s disease (AD). Published in Nature Communications, the study demonstrates that M4 effectively modulates amyloid-beta 42 (Aβ42) aggregation by binding with high affinity and stabilizing transient helical conformations, thereby preventing toxic beta-sheet assembly. In laboratory settings, M4 inhibited oligomer formation and remodeled pre-existing aggregates. In primary neuron cultures, the compound restored synaptic protein levels, reduced oxidative stress, and preserved mitochondrial membrane potential. Furthermore, trials using a 5xFAD mouse model showed that M4 significantly attenuated neuroinflammation, reduced overall Aβ burden, and improved cognitive performance. Pharmacokinetic analyses confirmed the molecule's favorable brain penetration and metabolic stability. These findings suggest that targeting the structural dynamics of Aβ through foldamer technology offers a promising strategy to mitigate AD pathology, addressing key drivers of neurotoxicity such as synaptic disruption and cellular homeostasis imbalance. The research highlights M4 as a viable candidate for further development in treating Alzheimer’s disease.
Wire timeline
Foldamer M4 Mitigates Alzheimer’s Pathology by Stabilizing Aβ Helical Domains
Researchers have identified a synthetic peptidomimetic foldamer, designated M4, as a potent therapeutic candidate for Alzheimer’s disease (AD). Published in Nature Communications, the study demonstrates that M4 effectively modulates amyloid-beta 42 (Aβ42) aggregation by binding with high affinity and stabilizing transient helical conformations, thereby preventing toxic beta-sheet assembly. In laboratory settings, M4 inhibited oligomer formation and remodeled pre-existing aggregates. In primary neuron cultures, the compound restored synaptic protein levels, reduced oxidative stress, and preserved mitochondrial membrane potential. Furthermore, trials using a 5xFAD mouse model showed that M4 significantly attenuated neuroinflammation, reduced overall Aβ burden, and improved cognitive performance. Pharmacokinetic analyses confirmed the molecule's favorable brain penetration and metabolic stability. These findings suggest that targeting the structural dynamics of Aβ through foldamer technology offers a promising strategy to mitigate AD pathology, addressing key drivers of neurotoxicity such as synaptic disruption and cellular homeostasis imbalance. The research highlights M4 as a viable candidate for further development in treating Alzheimer’s disease.
Nature Communications